Search for drugs:
Typing the drug name to query
ALISKIREN HEMIFUMARATE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- ADVERSE REACTIONS
- Clinical Trials Experience
- Aliskiren's effect on ECG intervals was studied in a randomized, double-blind, placebo and active-controlled (moxifloxacin), 7-day repeat dosing study with Holter-monitoring and 12 lead ECGs throughout the interdosing interval. No effect of aliskiren on QT interval was seen.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
14
24078
Other ADRs
21382
38360205
Odds Ratio = 1.044
Drug Property Information
ATC Code(s):
- C09XA02 - aliskiren hemifumarate
- C09XA - Renin-inhibitors
- C09X - OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C - CARDIOVASCULAR SYSTEM
- C09XA53 - aliskiren hemifumarate
- C09XA - Renin-inhibitors
- C09X - OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C - CARDIOVASCULAR SYSTEM
- C09XA52 - aliskiren hemifumarate
- C09XA - Renin-inhibitors
- C09X - OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C - CARDIOVASCULAR SYSTEM
- C09XA54 - aliskiren hemifumarate
- C09XA - Renin-inhibitors
- C09X - OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C - CARDIOVASCULAR SYSTEM
- C09DX02 - aliskiren hemifumarate
- C09DX -
- C09D - "ANGIOTENSIN II ANTAGONISTS, COMBINATIONS"
- C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C - CARDIOVASCULAR SYSTEM
Active Ingredient:ALISKIREN HEMIFUMARATE
Active Ingredient UNII:C8A0P8G029
Drugbank ID:DB09026
PubChem Compound:5493444
CTD ID: C446481
PharmGKB:PA143487910
CAS Number:173334-57-1
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 150.0 mg/day C09XA02
Chemical Structure: 
SMILE Code:
COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.